Resilience and Eli Lilly Invest $750M in Expanding US Medicines Production
Eli Lilly and Company has partnered with Resilience to invest $750 million in expanding the production of Lilly's KwikPen injectable device at a facility in Ohio. The initiative aims to strengthen supply for diabetes and obesity treatments, addressing rising patient demand across the U.S. This expansion builds on their 2023 partnership and will create over 400 new jobs, bringing total employment from Resilience’s operations in Ohio above 1,400. Operations at the expanded site are expected to begin by early 2027 after preparation has already started. The collaboration is part of a broader effort to scale up complex manufacturing programs and ensure consistent quality and supply for Lilly's medicines. To date, Resilience and Lilly have produced over 150 million doses in vial and pre-filled syringe formats. Resilience’s CEO emphasized the importance of trusted partnerships and operational excellence in strengthening America’s medicine supply chain. The partnership also benefits from workforce development support through local organizations like REDI Cincinnati.
Tickers: $LLY
Topics: Investment Job Creation Pharmaceuticals Supply Chain